Mimedx Group Inc Stock Price, News & Analysis

MiMedx Group has published a peer-reviewed study in the Journal of Investigative Dermatology, focusing on its Purion processed dehydrated human amnion/chorion membrane (dHACM). The research investigates the potential of dHACM to combat excessive fibrosis, affecting over 100 million people globally. Findings indicate that dHACM disrupts the TGF-β1 signaling pathway, regulating fibrotic activity and reducing pathological scar formation. MiMedx's CEO emphasized the continuous R&D investments to enhance understanding and application of their amniotic tissue technologies.

MIMEDX Group, Inc. (Nasdaq: MDXG) has received regulatory approval from the Japanese Ministry of Health for its EPIFIX allograft, allowing it to market this product in Japan. EPIFIX is designed to aid the healing of chronic wounds like diabetic foot ulcers and venous leg ulcers. The approval is projected to benefit up to 100,000 new patients annually. MIMEDX is now focusing on establishing reimbursement and distribution networks, aiming for EPIFIX availability in early 2022.

MIMEDX Group, an industry leader in regenerative medicine using amniotic tissue, announced that key executives will participate in a fireside chat at the Jefferies Virtual Healthcare Conference.

Date: June 4, 2021
Time: 2:00 PM ET
Webcast Link: Join Here

MIMEDX specializes in developing placental tissue allografts for healthcare sectors, processing tissues through proprietary methods and maintaining high production standards.

MIMEDX Group, Inc. (NASDAQ: MDXG) has extended the deadline for shareholders to pre-register for the 2021 Annual Meeting to May 26, 2021, at 10:00 a.m. Eastern Time. The virtual meeting is scheduled for May 27, 2021, at 10:00 a.m. Eastern. Shareholders are advised to pre-register to participate. Details on pre-registration can be found in the Company's definitive proxy statement or online at www.votemimedx.com. Shareholders eligible to vote must be on record as of April 16, 2021.

MIMEDX Group, a leader in regenerative medicine utilizing amniotic tissue, announced that CEO Timothy R. Wright and CFO Peter M. Carlson will participate in two upcoming virtual investor conferences. The first event is the Bank of America Securities 2021 Virtual Health Care Conference on May 13, 2021, at 2:45 PM ET, and the second is the Canaccord Genuity Virtual Musculoskeletal Conference on May 20, 2021, at 10:00 AM ET. Interested investors can access the webcasts through the company’s website and contact their representatives for meetings.

MIMEDX Group, Inc. (Nasdaq: MDXG) announced a collaborative agreement with the Wake Forest Institute for Regenerative Medicine to enhance scientific evidence supporting amniotic tissue therapies. This partnership aims to advance regenerative science and innovative biologics, with a focus on understanding product mechanisms and potential therapeutic targets. CEO Timothy R. Wright emphasized the importance of peer-reviewed data for patient care, while WFIRM's Dr. Anthony Atala expressed enthusiasm for the collaboration. MIMEDX continues to lead in amniotic tissue science and aims to develop next-generation therapies.

Prescience Point Capital Management has withdrawn its nominees for the MiMedx Group, Inc. (NASDAQ: MDXG) Board of Directors ahead of the Annual Meeting set for May 27, 2021. The firm believes its activism has led to significant improvements in corporate governance and a focus on enhancing shareholder value. Key governance proposals include lowering the special meeting ownership threshold from 50% to 25% and de-staggering the Board. Prescience Point remains a long-term stakeholder, emphasizing that MiMedx shares are undervalued, and encouraging shareholders to support the proposed changes.

MIMEDX Group, Inc. (NASDAQ: MDXG) urges shareholders to scrutinize Prescience Point's motives in its proxy fight for board influence. The Company highlights concerns over Prescience Point's trading practices, suggesting self-serving interests, and questions the qualifications of its nominees. MIMEDX emphasizes its turnaround success since appointing CEO Timothy R. Wright, noting a 237% increase in stock value and renewed credibility with the FDA. Shareholders are encouraged to vote for MIMEDX’s qualified directors at the upcoming Annual Meeting on May 27, 2021, to protect their investments.